158 related articles for article (PubMed ID: 36989073)
1. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.
Grant SJ; Wildes TM; Rosko AE; Silberstein J; Giri S
Cancer; 2023 Jul; 129(13):2023-2034. PubMed ID: 36989073
[TBL] [Abstract][Full Text] [Related]
2. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
Medhekar R; Ran T; Fu AZ; Patel S; Kaila S
BMC Cancer; 2022 Aug; 22(1):901. PubMed ID: 35982416
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Cejalvo MJ; Bustamante G; González E; Vázquez-Álvarez J; García R; Ramírez-Payer Á; Pérez-Persona E; Abella E; Garzón S; García A; Jarque I; González MS; Sampol A; Motlló C; Martí JM; Alcalá M; Duro R; González Y; Sastre JL; Sarrà J; Lostaunau G; López R; de la Rubia J
Ann Hematol; 2021 Jul; 100(7):1769-1778. PubMed ID: 33885924
[TBL] [Abstract][Full Text] [Related]
6. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
Du C; Li L; Fan H; Mao X; Liu J; Xu Y; Sui W; Deng S; Li C; Zhao J; Yi S; Hao M; Zou D; Zhao Y; Qiu L; An G
Hematology; 2023 Dec; 28(1):2258686. PubMed ID: 37724573
[TBL] [Abstract][Full Text] [Related]
7. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
8. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
9. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
11. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
[TBL] [Abstract][Full Text] [Related]
12. Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data.
Kim C; Hernandez RK; Cyprien L; Liede A; Cheng PC
Support Care Cancer; 2018 Aug; 26(8):2833-2841. PubMed ID: 29516168
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F; Cheng Q; Song K; Yu H; Li J; Zhang H; Hu G; Zhou M; Wang J; Ding Z; Luo Z; Peng T; Ding L; Zhao L; Liu J; He Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 47(4):497-504. PubMed ID: 35545345
[TBL] [Abstract][Full Text] [Related]
14. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legieć W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špička I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
Lancet Haematol; 2022 Jun; 9(6):e403-e414. PubMed ID: 35550060
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
16. Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice.
Xia J; Wang L; Zhou X; Wang J; Wang H; Guo H
J Int Med Res; 2018 Jun; 46(6):2230-2237. PubMed ID: 29584537
[TBL] [Abstract][Full Text] [Related]
17. Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.
Kumar S; Williamson M; Ogbu U; Surinach A; Arndorfer S; Hong WJ
Cancer Med; 2021 Sep; 10(17):5866-5877. PubMed ID: 34402201
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma.
Huang CT; Liu CJ; Ko PS; Liu HT; Yu YB; Hsiao LT; Gau JP; Tzeng CH; Chiou TJ; Liu JH; Yang MH; Huang LJ; Liu CY
BMC Infect Dis; 2017 Jan; 17(1):33. PubMed ID: 28056867
[TBL] [Abstract][Full Text] [Related]
19. Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting.
Vargas-Serafin C; Acosta-Medina AA; Ordonez-Gonzalez I; Martínez-Baños D; Bourlon C
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):182-187. PubMed ID: 33414064
[TBL] [Abstract][Full Text] [Related]
20. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
